Rate this item
(0 votes)

Tehila Sonnenfeld, Ph.D.

By Super User 24 November, 2015 1692

Director of Manufacturing and Manager of Technology Transfer. Dr. Sonnenfeld joined the Company in 2009 as a Project Manager for the development of the Company’s personalized CRCL vaccine. She was promoted in 2012 to the position of Director of manufacturing and been serving in that position since then. Dr. Sonnenfeld has a Ph.D. in Biochemistry from the Hebrew University and has published several publications in the field of proteins interactions.

Share

SPECIALITY INFORMATION

patients


Treatment strategy designed to use the power of the human immune system to kill tumors and prevent their recurrence.
No requirement for a matched donor or chemotherapy/radiation conditioning prior to treatment.
Innovative technology – proven and non-toxic.
read more

Healthcare professionals


Therapeutic anti-tumor vaccine developed from core break-through technology called the "Mirror Effect™“ which opens a pathway to treating patients with metastatic cancer that have failed all available therapy options.
Elicits a GVT-like mechanism without the GVHD toxicity.
read more

Investors


Privately-held Israeli biopharmaceutical company spin out from Hadassah-Hebrew University Medical Center with headquarters in Jerusalem.

Over 200 individual private shareholders and grant support from the Israel Office of the Chief Scientist.
read more